INBPOTCPharmaceutical PreparationsFiscal year ends June 30
INTEGRATED BIOPHARMA INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.18+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $5.59M
- P/E (TTM)
- –
- Dividend yield
- –
INTEGRATED BIOPHARMA INC revenue by segment
By business segment
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing [Member] | $9.48M | $9.82M | $10.92M | $12.17M | $13.58M | $13.46M | $11.67M | $12.97M | $12.33M | $12.75M | $11.05M | $12.44M | 96.8% | -30.2% |
| Other Nutraceutical Business [Member] | $318.00K | $284.00K | $360.00K | $522.00K | $595.00K | $488.00K | $944.00K | $644.00K | $418.00K | $397.00K | $456.00K | $478.00K | 3.2% | -46.6% |
By product or service
By region
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $7.72M | $8.15M | $8.71M | $10.65M | $11.22M | $10.72M | $10.26M | $11.43M | $10.02M | $11.17M | $9.85M | $11.31M | 78.8% | -31.2% |
| Non-US [Member] | $2.07M | $2.00M | $2.58M | $2.04M | $2.96M | $3.23M | $2.36M | $2.19M | $2.73M | $1.98M | $1.66M | $1.61M | 21.2% | -29.9% |
| Europe and Canada [Member] | – | – | – | – | – | – | – | – | – | – | $1.66M | $1.61M | – | – |
| Europe [Member] | – | $1.96M | $2.58M | $2.04M | – | $3.23M | $2.36M | $2.19M | – | $1.98M | $1.66M | $1.61M | – | – |
From the segment and revenue-disaggregation notes of Integrated Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.